Psoriatic Arthritis

Christopher Ritchlin, MD, MPH, discusses the safety and efficacy of bimekizumab in patients with psoriatic arthritis, the BE ACTIVE study, the clinical significance of these results, and his plans for future research on this topic.

The US Food and Drug Administration (FDA) has delayed its decision on upadacitinib (RINVOQ) for the for the treatment of adults with active psoriatic arthritis and adults with active ankylosing spondylitis.

In patients with early inflammatory arthritis, a serum protein biomarker panel was proven effective in separating patients with psoriatic arthritis from those with rheumatoid arthritis.

Upadacitinib (UPA) effectively treated patients with psoriatic arthritis (PsA) and axial involvement, a group that is historically more likely to have higher disease burden and more quality-of-life impairments than patients without axial involvement.

Rheumatology Network interviewed Hermine Brunner, MD, MSc, MBA, lead investigator of the JUNIPERA study, which reported on the safety and efficacy of secukinumab for patients with juvenile idiopathic arthritis (JIA), presented at the EULAR 2021 Virtual Congress. Secukinumab was the first approved biologic for specific JIA categories in the US and marked improvement of skin involvement with juvenile spondyloarthritis (jPSA) and increased quality of life for children with chronic arthritis plus psoriasis.

In patients with psoriatic arthritis (PsA), guselkumab (Tremfya, Janssen Immunology) treatment reduced serum protein levels of acute phase and T-helper cell 17 (Th17) effector cytokines, achieving comparable levels to those in healthy controls.

In partnership with CreakyJoints, Alexis Ogdie, MD discusses her study, “Real-World Patient Experience and Treatment Preferences in Patients With Psoriatic Arthritis,” which was recently presented at the EULAR 2021 Virtual Congress.

Risankizumab showed significantly greater improvements in symptoms of psoriatic arthritis when compared with a placebo and was well tolerated in patients who were intolerant to biologics and conventional synthetic disease-modifying antirheumatic drugs.

Alyssa Johnsen, MD, PhD, spoke with Rheumatology Network about the efficacy of guselkumab for psoriatic arthritis, the challenges of delivering safe and effective treatments in this patient population, and how guselkumab can help improve physical, social, and work activity for these patients.

In addition to swollen joint count, joint location and functional impairment should also be considered when describing psoriatic arthritis as moderate.

Data from the COSMOS study showed that 44.4% of patients who received guselkumab versus 19.8% of patients who received placebo achieved a ≥20% improvement at week 24.

Rheumatology Network interviewed Laura Coates, MBChB, MRCP, PhD, to discuss what her recent study adds to existing psoriatic arthritis (PsA) research, what some of the key factors are that impact a patient’s opinion of remission, and the clinical significance.

Catch up on Rheumatology Network's most recent highlights in psoriatic arthritis news.

For patients with psoriatic arthritis (PsA), multidomain disease was associated with worse measures of disease activity, quality of life, and work productivity.

Investigators utilized study data to further investigate the concept of patient-defined remission and identify which factors were associated with patient-defined remission or low disease activity.

A combination of adalimumab (ADA) treatment and patient support programs (PSPs) may reduce opioid use and increase medication adherence.

Patients with psoriatic arthritis and minimal disease activity who continued ixekizumab therapy fared significantly better than those who stopped using the drug, including fewer relapses related to disease activity.

A recent study explores the correlation between work obligations and anxiety in patients with inflammatory rheumatic diseases during the second wave of the COVID-19 pandemic. Poor quality of life due to self-isolation has been reported in this patient population.

"Our results suggest that there are likely to be certain treatments that will confer preferential response in psoriatic arthritis (PsA), including tumor necrosis factor (TNF) inhibitors and IL-17 medications, compared to other options," stated Jeffrey Curtis, MD.

In today’s episode of Overdrive by Rheumatology Network, we sat down with Philip J. Mease, MD, to discuss his study, “Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.”

Catch up on Rheumatology Network's most recent highlights in psoriatic arthritis news.

Patients with oligoarticular psoriatic arthritis (PsA) receiving apremilast monotherapy fared better than those who initiated methotrexate (MTX) therapy or biologic disease-modifying antirheumatic drug (bDMARD) initiators.

While men with inflammatory arthritis drink significantly more alcohol and have less severe disease activity, alcohol is not linked to disease remission.

Investigators observed that patients treated with secukinumab were more likely to achieve Psoriasis Area Severity Index (PASI) 75/90/100 responses and Investigator’s Global Assessment (IGA) improvement at 52 weeks than those administered usetkinumab, regardless of their psoriatic arthritis (PsA) status.

This week, Rheumatology Network sat down with Philip J. Mease, MD, to discuss his study, “Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.”